Naratriptan: profile and news

Allergan Enters Into Agreement with GlaxoSmithKline to Accelerate ... Oct 3, 2005
...type A) in Japan and China and to co-promote GSK's products IMITREX STATdose System(R) (sumatriptan succinate) and AMERGE(R) (naratriptan hydrochloride) in the ... - PharmaLive.com (press release),

E-prescribing System Had No Effect on Formulary Compliance or ... Jun 6, 2005
...mg. The cost to successfully treat one patient-episode ranged from $56.30 for eletriptan 40 mg to $111.36 for naratriptan 2.5 mg. ... - Market Wire (press release)

Used to treat: Severe migraine attacks Apr 24, 2005
Triptans can cause nausea, fatigue and vomiting, as well as sensations of heat and heaviness. Naratriptan can cause visual disturbances and a racing heart. - Scotsman

/FIRST ADD -- NYTU041B -- Pfizer Inc Earnings/ Apr 19, 2005
Relpax 40 mg also provides significantly more sustained relief than zolmitriptan (Zomig) or naratriptan (Amerge) based on two comparator studies. ... - PR Newswire

Triptan Nonresponder Studies: Implications for Clinical Practice Mar 7, 2005
Two-hour pain-relief rates of 25% to 81% using alternative triptans (naratriptan, almotriptan, eletriptan, zolmitriptan, and rizatriptan) have been reported in ... - Medscape (subscription)

Other information

Indication
For the acute treatment of migraine attacks with or without aura in adults.

Pharmacology
Naratriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Naratriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Naratriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT_1D family) having only a weak affinity for significant affinity or pharmacological activity at 5-HT₂, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Naratriptan also activates 5-HT₁ receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Naratriptan in humans.

Mechanism Of Action
Naratriptan binds with high affinity to human 5-HT_1B and

Drug Category
Vasoconstrictor Agents; Selective Serotonin Agonists; ATC:N02CC02

Brand Names/Synonyms
Amerge; CHEMBANK1626; Naratriptan

Dosage Forms
TABLET

Absorption
Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours

Interactions
-->Interactions for Naratriptan:

Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.

The administration of naratriptan with other 5-HT₁ agonists has not been evaluated in migraine patients. Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT₁ agonists within 24 hours of each other is not recommended.

Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists. If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.

Drug/ Laboratory Test Interactions

AMERGE Tablets are not known to interfere with commonly employed clinical laboratory tests.

Chemical IUPAC Name
N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide

Chemical Formula
C17H25N3O2S

Half Life
5-8 hours

Drug Type
Approved Drug

# Accession No
APRD00220

CAS Registry Number
121679-13-8